

Pallawi Torika

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3200448/publications.pdf>

Version: 2024-02-01

67
papers

807
citations

567281

15
h-index

526287

27
g-index

68
all docs

68
docs citations

68
times ranked

1491
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. <i>Journal of Clinical Oncology</i> , 2017, 35, 2260-2267.	1.6	132
2	Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies. <i>Blood</i> , 2021, 138, 811-814.	1.4	81
3	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	7.0	80
4	NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 522-536.	4.9	69
5	NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 123-135.	4.9	43
6	NCCN Guidelines Insights: Hodgkin Lymphoma, Version 2.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 322-334.	4.9	35
7	NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1460-1467.	4.9	30
8	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020, 4, 253-262.	5.2	29
9	Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Oncologist</i> , 2020, 25, 878-885.	3.7	28
10	Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 426-438.	2.3	23
11	Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study. <i>Blood</i> , 2020, 136, 35-36.	1.4	23
12	Swallowing a bitter pill—oral arsenic trioxide for acute promyelocytic leukemia. <i>Blood Reviews</i> , 2016, 30, 201-211.	5.7	22
13	Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma. <i>Cancer & Metabolism</i> , 2020, 8, 10.	5.0	19
14	Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. <i>British Journal of Haematology</i> , 2020, 191, 44-51.	2.5	19
15	Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. <i>Cancer</i> , 2020, 126, 293-303.	4.1	18
16	Cotton Fever: An Evanescent Process Mimicking Sepsis in an Intravenous Drug Abuser. <i>Journal of Emergency Medicine</i> , 2013, 44, e385-e387.	0.7	12
17	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. <i>Blood Advances</i> , 2022, 6, 2035-2044.	5.2	12
18	Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. <i>Blood Cancer Discovery</i> , 2022, 3, 181-193.	5.0	12

#	ARTICLE	IF	CITATIONS
19	Pevonedistat, a NEDD8-activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre-clinical models of diffuse large B-cell lymphoma. <i>EJHaem</i> , 2020, 1, 122-132.	1.0	10
20	Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2020, 189, 313-317.	2.5	7
21	Utility of bone marrow aspirate and biopsy in staging of patients with T-cell lymphoma in the PET-Era – tissue remains the issue. <i>Leukemia and Lymphoma</i> , 2020, 61, 3226-3233.	1.3	7
22	Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. <i>Oncologist</i> , 2020, 25, e993-e997.	3.7	7
23	Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Blood</i> , 2018, 132, 1626-1626.	1.4	7
24	Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis. <i>Blood</i> , 2020, 136, 4-6.	1.4	7
25	Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 884-884.	1.4	7
26	Cannabinoid and Hyperemesis. <i>Mayo Clinic Proceedings</i> , 2012, 87, 502-503.	3.0	6
27	A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e51-e60.	0.4	6
28	Analysis of Outcomes and Predictors of Response in Patients with Relapsed Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel. <i>Blood</i> , 2021, 138, 1756-1756.	1.4	6
29	Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 77-85.	2.4	4
30	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019, 134, 502-502.	1.4	4
31	MCL-1 Inhibition By the Selective MCL-1 Inhibitor AMG-176 Induces in Vitro Activity Against Burkitt Lymphoma Cell Lines and Synergistically Enhances the Cytotoxic Effect of Chemotherapy and BH3 Mimetics. <i>Blood</i> , 2019, 134, 5303-5303.	1.4	4
32	Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis. <i>Blood</i> , 2020, 136, 2-3.	1.4	4
33	High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers. <i>Blood</i> , 2021, 138, 455-455.	1.4	4
34	Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers. <i>Blood</i> , 2018, 132, 451-451.	1.4	3
35	Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 5301-5301.	1.4	3
36	Frequency and timing of other primary cancers in patients with chronic lymphocytic leukemia (CLL): a 17-year longitudinal study. <i>Leukemia and Lymphoma</i> , 2022, , 1-10.	1.3	3

#	ARTICLE	IF	CITATIONS
37	Treatment Strategies for Advanced Classical Hodgkin Lymphoma in the Times of Dacarbazine Shortage. JCO Oncology Practice, 2022, 18, 491-497.	2.9	3
38	Dose Reductions in Ibrutinib Therapy Are Not Associated with Inferior Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 5567-5567.	1.4	2
39	Inhibition of Nuclear Factor Kappa B (NFkB)/Interferon Regulatory Factor 4 (IRF4) Signaling Pathway in Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) By Combining MLN4924, a Novel NEDD8 Activating Enzyme Inhibitor (NAE) and Ibrutinib. Blood, 2014, 124, 1768-1768.	1.4	2
40	Benefit of Consolidative Autologous Stem Cell Transplantation in First Complete Remission for Patients with Double Hit Lymphoma Appears Dependent on Induction Regimen Intensity. Blood, 2016, 128, 3455-3455.	1.4	2
41	A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL). Blood, 2021, 138, 2433-2433.	1.4	2
42	BRD4 Inhibitors Enhance the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia. Blood, 2020, 136, 37-37.	1.4	2
43	Microbial Patterns in Severe Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation: Results From a Tertiary Care Center in India. Chest, 2010, 138, 800A.	0.8	1
44	Successful Treatment of Paraneoplastic Cholestasis in Relapsed/Refractory Hodgkin Lymphoma With Bridging Therapy and Checkpoint Blockade. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e316-e319.	0.4	1
45	Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy. Blood, 2018, 132, 453-453.	1.4	1
46	Effect of Immune Reconstitution on Survival after Autologous Hematopoietic Cell Transplant for B-Cell Non-Hodgkin Lymphoma. Blood, 2015, 126, 3173-3173.	1.4	1
47	Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study. Blood, 2019, 134, 2817-2817.	1.4	1
48	Utility of Bone Marrow Biopsy in the Staging of T-Cell Lymphoma in the PET-CT Era. Blood, 2019, 134, 4039-4039.	1.4	1
49	Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices. Blood, 2021, 138, 532-532.	1.4	1
50	Determinants of COVID-19 Vaccine Response in Patients with Lymphoma on B Cell Directed Therapy. Blood, 2021, 138, 1340-1340.	1.4	1
51	Peg-filgrastim potentiates rituximab in patients with indolent lymphomas: results of a phase II study. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S72.	0.4	0
52	Immune Reconstitution after Autologous Hematopoietic Cell Transplant (AHCT) in B-Cell Non-Hodgkin Lymphoma (B-NHL) Patients Mobilized with Granulocyte Colony Stimulating Factor (G-CSF), with or without Plerixafor. Biology of Blood and Marrow Transplantation, 2016, 22, S155-S156.	2.0	0
53	Is CLL the Second Cancer? A Single Center Retrospective Analysis of Secondary Malignancies (SM) in Patients with Chronic Lymphocytic Leukemia (CLL). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S219.	0.4	0
54	Successful use of venetoclax for treatment of eosinophilic dermatosis of myeloproliferative disease in a patient with chronic lymphocytic leukemia. Annals of Hematology, 2020, 99, 1129-1131.	1.8	0

#	ARTICLE	IF	CITATIONS
55	Evaluation Of Laboratory and Clinical Markers For Predicting Survival In TTP/HUS: A Single Center Retrospective Study. Blood, 2013, 122, 1082-1082.	1.4	0
56	Intense Cytarabine-Based Chemo-Immunotherapy, Central Nervous System (CNS) Prophylaxis and Early High-Dose Chemotherapy and Autologous Stem Cell Support (HDC-ASCS) in First Remission Are Associated with an Improved Clinical Outcome in Double-Hit (DHL)/Triple-Hit (THL) Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2014, 124, 3031-3031.	1.4	0
57	Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study. Blood, 2015, 126, 3975-3975.	1.4	0
58	Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. Blood, 2018, 132, 93-93.	1.4	0
59	Outcomes of Follicular Lymphoma (FL) with Early Progression (EP): Does Choice of Second Line Therapy Impact the Course of Disease?. Blood, 2018, 132, 4156-4156.	1.4	0
60	BCL-XI Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2019, 134, 1629-1629.	1.4	0
61	Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Cell Lymphoma- a Single Center Experience. Blood, 2019, 134, 4058-4058.	1.4	0
62	Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients. Blood, 2021, 138, 4066-4066.	1.4	0
63	Impact of Anticonvulsant - Methotrexate Interactions on High Dose Methotrexate Clearance and Outcomes in Patients with Primary CNS Lymphoma. Blood, 2021, 138, 4358-4358.	1.4	0
64	Evaluating the Role of Baseline Geriatric Assessment in Predicting Quality of Life in Older Adults with Non-Hodgkin Lymphoma on Oral Targeted Therapies. Blood, 2021, 138, 4094-4094.	1.4	0
65	Potentiate Immune Activation and Function By Targeting Inhibitor of Apoptosis Proteins (IAPs) in Relapse/Refractory DLBCL. Blood, 2020, 136, 30-31.	1.4	0
66	Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era. Blood, 2020, 136, 24-26.	1.4	0
67	EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort. Blood, 2020, 136, 4-6.	1.4	0